Roughly 20 percent of diagnosed breast cancers are human epidermal growth factor receptor 2-positive, or HER2+. Compared with other breast cancers, HER2+ breast cancers tend to spread faster and more aggressively. Patients with HER2+ breast cancer are more likely to experience recurrence following treatment. In a recent study, researchers started out with an objective of investigating how trastuzumab and lapatinib affected HER2+ breast cancer tumors in the short window between diagnosis and surgery. Initially, they had separated study participants into three separate groups (trastuzumab, lapatinib, and no treatment) but decided half way through to amend the study. Those in the lapatinib group were instead given trastuzumab and lapatinib. The results were HUGE. For 11% of those taking the drug combo, the drugs had eradicated their tumors, while 17% of women treated with the drug combo had minimal residual disease. Read more about this hope-inspiring research here.